Novartis is a Swiss drugmaker with medicines across heart disease, cancer and immunology.
Novartis AG (NVS) is expected to report earnings on Tuesday, October 27, 2026, before the open. Estimated release time before open. Consensus EPS estimate is $2.25.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-21 | Jun 2026 qtr | $2.17 | $2.41 | +11.1% | $14.42B |
| 2026-04-28 | Mar 2026 qtr | $2.11 | $1.65 | — | $13.52B |
| 2026-02-04 | Dec 2025 qtr | $1.99 | $2.03 | +2.0% | $13.33B |
| 2025-10-27 | Sep 2025 qtr | $2.26 | $2.25 | -0.4% | $14.36B |
| 2025-07-17 | Jun 2025 qtr | $2.38 | $2.42 | +1.7% | $14.84B |
| 2025-03-31 | Mar 2025 qtr | $2.12 | $2.28 | +7.5% | $13.62B |
| 2025-01-31 | Dec 2024 qtr | $1.80 | $1.98 | +10.0% | $13.56B |
| 2024-09-30 | Sep 2024 qtr | $1.94 | $2.06 | +6.2% | $13.17B |
NVS has beaten consensus EPS in 6 of its last 7 scored quarters.
NVS pays a annual dividend, currently yielding 3.04%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-03-11 | $4.7402 | 2026-03-16 |
| 2025-03-12 | $3.994 | 2025-04-25 |
| 2024-03-07 | $3.1986 | 2024-04-19 |
| 2023-03-09 | $3.4987 | 2023-03-20 |
| 2022-03-08 | $3.3253 | 2022-03-17 |
| 2021-03-04 | $3.1991 | 2021-03-15 |